Back pain
Drug research and approvals for back pain: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 434 studies of back pain are recruiting on ClinicalTrials.gov, and Health Canada has authorized 5 drug trials for it since 2013.
- Recruiting worldwide: 434
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 0
- Efficacy of Automated Tuina and Acupuncture for Treating Chronic Lower Back PainNCT07945197 · Not applicable · Nanyang Technological University · starts Jan 1, 2025
- Pectoral Nerve Block Versus Serratus Posterior Superior Intercostal Plane Block for Pain Control After MastectomyNCT07929090 · Not applicable · Bursa City Hospital · starts Nov 1, 2026
- Ultrasound-Guided Thoracolumbar Fascia Injection for Chronic Low Back Pain in Patients With Type 2 DiabetesNCT07927530 · Not applicable · Hatice Zehra FERHATLAR · starts Oct 23, 2026
- The Hidden Burden of Cerebral Palsy: Exploring the Relationship Between Gross Motor Function of Children, Maternal Low…NCT07919002 · Not reported · October 6 University · starts Oct 13, 2026
- A Novel Treatment for Chronic Low Back Pain Using Multi Angular Isometric Lumbar Exercise: Randomized Clinical Trial.NCT07908693 · Not applicable · Hamad Medical Corporation · starts Jun 22, 2025
- Effect of Ultrasound-Guided Posterior Cutaneous Nerve of the Forearm Epicondylar Branch Block on Pain and Function in…NCT07894718 · Not applicable · Gaziler Physical Medicine and Rehabilitation Education and Research Hospital · starts Oct 25, 2025
- The Intervention Effect of Exercise on Lumbar Multifidus Muscle InjuriesNCT07892846 · Not applicable · Chinese PLA General Hospital · starts Oct 26, 2026
- Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery.NCT07878156 · Phase 3 · Children's Cancer Hospital Egypt 57357 · starts Dec 17, 2025
- Effects of Virtual Reality Exergames Versus Spinal Manipulation in Chronic Nonspecific Low Back PainNCT07876960 · Not applicable · Cairo University · starts Oct 20, 2026
Approved 10
- NaproxenCyclooxygenase inhibitor
- AcetaminophenCyclooxygenase inhibitor
- LidocaineSodium channel alpha subunit blocker
- IbuprofenCyclooxygenase inhibitor
- ChlorpheniramineHistamine H1 receptor antagonist
- MentholTransient receptor potential cation channel subfamily M member 8 opener
- CapsaicinVanilloid receptor opener
- AspirinCyclooxygenase inhibitor
- Methyl salicylate
- Camphor
Phase 3 12 of 21
- OxycodoneMu opioid receptor agonist
- BuprenorphineMu opioid receptor agonist
- DuloxetineSerotonin transporter inhibitor
- KetorolacCyclooxygenase inhibitor
- HydromorphoneMu opioid receptor agonist
- MilnacipranSerotonin transporter inhibitor
- MorphineMu opioid receptor agonist
- SufentanilMu opioid receptor agonist
- TapentadolMu opioid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- LevobupivacaineSodium channel protein type IV alpha subunit blocker
- Risedronic acidFarnesyl diphosphate synthase inhibitor
Phase 2 10
- CelecoxibCyclooxygenase-2 inhibitor
- ClonidineAdrenergic receptor alpha-2 agonist
- DesipramineNorepinephrine transporter inhibitor
- NaltrexoneOpioid receptors; mu/kappa/delta antagonist
- LoratadineHistamine H1 receptor antagonist
- CarbidopaDOPA decarboxylase inhibitor
- LevodopaDopamine D3 receptor agonist
- BenztropineMuscarinic acetylcholine receptor M1 antagonist
- Arbaclofen placarbilGABA-B receptor agonist
- FasinumabBeta-nerve growth factor inhibitor
Phase 1 or earlier 2
- Phenol
- Tranexamic acidPlasminogen inhibitor
How its trials ended
2,498 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 417 whose ending is known, 52% met their primary endpoint, 8% missed it and 40% stopped early.
- Completed, result not reported1,25550%
- Ongoing45518%
- Status unknown37115%
- Met its primary endpoint2159%
- Stopped: other or unclear914%
- Stopped: enrollment or feasibility432%
- Missed its primary endpoint351%
- Stopped: sponsor or business decision151%
- Stopped: funding12<1%
- Stopped: lack of efficacy5<1%
- Stopped: safety1<1%
| Aug 27, 2021 | Hindering the synaptic reconsolidation with the help of propranolol: a feasibility study of a novel approach for the treatment of chronic painPropranolol | Université De Sherbrooke | Closed |
| Feb 5, 2018 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of fasinumab in patients with moderate-to-severe chronic low…REGN475 (fasinumab) | Regeneron | Ongoing |
| Jan 8, 2016 | A randomized, double-blind, multi-dose, placebo-controlled phase 2/3 study to evaluate the efficacy and safety of fasinumab in patients with moderate to severe…REGN475 (fasinumab / Sar 164877) | Regeneron | Ongoing |
| Oct 29, 2015 | Genetic variants associated with the occurrence of localized low back pain or low back pain with widespread pain symptoms, and their response to treatment with…Propranolol | McGill University | Ongoing |
| Jul 23, 2015 | A phase 3, randomized, double-blind, placebo and active-controlled, multicenter, parallel-group study of the analgesic efficacy and safety of tanezumab in…PF-04383119 (tanezumab) | Pfizer | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA